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Detection of anti-D following
antepartum injections of Rh
immune globulin
M.S. KENNEDY, J. MCNANIE, AND A.WAHEED
Antepartum prophylaxis using Rh immune globulin (RhIG) at 28
weeks of gestation is routine in unsensitized Rh-negative women. As
various sources state that anti-D may be detected up to 6 months
after administration, we reviewed the medical and laboratory records
of all Rh-negative women who delivered at our institution during
1995. For 385 evaluable women, only 137 (35.6%) had anti-D demon-
strable in their sera at delivery; 97.8 percent of these delivered with-
in 75 days after administration of RhIG. Of 248 women (64.4%) who
delivered in < 76 days after administration of RhIG, 134 (54%) had
demonstrable anti-D. For 123 women who delivered between 76 to
95 days after RhIG, only 3 (2.4%) had demonstrable anti-D. Of 14
women who delivered more than 96 days after RhIG, none had anti-
D at delivery. These data show that the 300-μg dose used in the
United States may not be adequate for antepartum protection and
that the detection of anti-D more than 100 days after the administra-
tion of RhIG should be viewed with suspicion. Immunohema-
tology 1998;14:138–140.
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Antepartum administration of a 300-μg dose of Rh
immune globulin (RhIG) at 28 weeks gestation has
resulted in a decrease in the incidence of Rh immuniza-
tion in D– women from about 1–1.5 percent, with post-
partum administration only, to about 0.1–0.16 percent.1
Anti-D is demonstrable in the sera of these women with-
in a week of injection.The American Association of Blood
Banks’Technical Manual2 states that anti-D due to RhIG
may remain detectable for as long as 6 months. In addi-
tion, Konugres3 states that injected RhIG may be detect-
ed 5 to 6 months using some sensitive methods.
We reviewed the test results of 385 D– females who
received RhIG at 28 weeks gestation to see if we could
detect anti-D in third trimester antibody screens and
whether anti-D could be detected at delivery in these
females.
Materials and Methods
The medical and laboratory records of all D– women
who delivered at the Ohio State University Medical
Center during 1995 were reviewed to determine the
date of RhIG (RhoGAM™ Rho (D) Immune Globulin,
Ortho-Clinical Diagnostics, Raritan, NJ) administration,
the dates and results of the ABO and Rh type and anti-
body screen,and the intervals between these events.For
patients seen in the outpatient clinics, the RhIG admin-
istration logs were matched with the delivery logs of the
hospital. For patients seen in physicians’ offices, records
were retrieved and reviewed. Patients were included
regardless of the ABO and Rh type of their newborns and
the parity of the mothers.
The ABO, Rh, and antibody detection tests were per-
formed by tube techniques using monoclonal antisera
(Gamma Biologicals,Houston,TX) according to the man-
ufacturer's instructions. All nonreactive anti-D results
were tested for weak D with anti-human globulin (AHG).
Only AHG-negative women were included. Antibody
detection was performed by the addition of polyethy-
lene glycol (PEG; PeG, Gamma Biologicals) with conver-
sion to an AHG test using an anti-IgG reagent (Gamma
Biologicals).
For sensitivity studies, 0.1 mL was removed from the
300-μg vial (0.7 mL) of RhIG and used to make serial
dilutions to 1:4,000,000 in 0.9% sodium chloride (saline)
and was tested using PEG, saline to AHG, and albumin to
AHG techniques.
Results
For 385 confirmed D– women, the date of RhIG injec-
tion was reliably established by log entries. Only 137
women (35.6%) had anti-D demonstrable in their sera at
delivery (Table 1) and 134 (97.8%) of these 137 women
with anti-D delivered within 75 days after RhIG. For 248
women (64.4%) who delivered within 75 days of RhIG,
only 134 (54%) had demonstrable anti-D at delivery
(Table 1). For 123 women (31.9%) who delivered 76 to
95 days after administration of RhIG, only 3 (2.4%) had
demonstrable anti-D at delivery (Tables 1 and 2). Of 14
women (3.6%) who delivered more than 95 days after
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mary immunization can be prevented by injecting as lit-
tle as 20 μg of anti-D for each mL of D+ RBCs.Additional
studies reported that as little as 14.6 μg of anti-D per mL
of RBCs is immunosuppressive when the amount of D+
RBCs is 200 mL.8 However, 20 μg/mL appears to be the
lower limit when small volumes of RBCs are involved. In
addition, studies by Contreras and Mollison appeared to
indicate augmentation of primary immunization when 1
μg of anti-D was injected for 0.8 mL RBCs, in that 9 of 13
subjects developed anti-D compared with 4 of 12 who
received only 1 mL RBCs and no anti-D.9,10 Mollison
cites a larger study by Ascari (personal communication)
in which 103 of 134 developed anti-D after receiving 7
mL RBCs and 1.4 μg/mL of anti-D.5
Mollison speculated that at least 25 μg of anti-D
should be present just before delivery.1 A 300-μg dose at
28 weeks would give this level, assuming a T 1/2 of 26
days and that all the anti-D is circulating.1 However,stud-
ies by Bowman and Pollack have shown these assump-
tions to be incorrect,as the amount of IgG3 with T 1/2 of
7 days reduces the estimations by about 20 to 25 per-
cent.4 Our studies, detecting 18 ng/mL (54μ/3000 mL),
would thus suggest that those women without
detectable anti-D between 1 and 70 days postinjection
may not be adequately covered. Because large fetal
maternal hemorrhages of > 1 mL are unusual during
pregnancy and delivery, the number of women at risk
may be small.4 Bowman reports that in some of their
antenatal failures, the interval between antenatal pro-
phylaxis and delivery was 13.5 to 15 weeks.11Therefore,
he recommends that a second dose be given 12 weeks
after the first, even if the mother has not delivered.
Mollison states that the 100-μg dose, given at 28 and 34
weeks gestation as practiced in the United Kingdom will
result in a slightly higher amount of anti-D at delivery.1
In conclusion, anti-D detected more than 4 months
after RhIG administration is most likely due to active
immunization. At the minimum, an additional dose
should be given 12 weeks after the antenatal dose.
Further studies are required to assess the need for addi-
tional doses.
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RhIG injection, none had detectable anti-D at delivery
(Table 1).For the women who delivered between 75 and
105 days after RhIG administration, the data in 5-day
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Table 1. Detectable anti-D in relation to days from Rh immune globulin
administration until delivery.
Subjects (%) Anti-D (%)
1–75 days 248 (64.4%) 134 (54.0%)
76–95 days 123 (31.9%) 3 (2.4%)
96–105 days 14 (3.6%) 0 (0.0%)
Totals 385 (100.0%) 137 (35.6%)
Table 2. Number of women with anti-D when interval between RhIG
administration and testing was > 75 days






In the dilution studies,our routine antibody detection
technique could detect a 1:64,000 dilution using PEG, a
1:32,000 dilution in albumin to AHG,and a 1:16,000 dilu-
tion in saline to AHG. Assuming the intended dose is 300
μg in 0.5 mL (perhaps an overestimation as overfill of
vials is generally 10%), the starting volume represents 60
μg. The 1:64,000 dilution would represent 1.8 ng, the
1:32,000 would represent 3.6 ng, and the 1:16,000
would represent 7.3 ng. Thus, PEG at 1:64,000 could
detect a concentration of about 18 ng/mL (1.8 ng in 0.1
mL).As our starting concentration may have been over-
estimated, the PEG technique may actually detect lower
concentrations.
Discussion
Our data as well as that of other investigators4,5
strongly suggest that detecting circulating anti-D using
routine immunohematology methods is unlikely 6
months after injection of RhIG. The “six months” state-
ment in the Technical Manual is unreferenced and has
been present in the 10th and subsequent editions.2 In a
study of volunteers who were injected with a 1000-μg
vial of RhIG, the concentration of anti-D was 207 ng/mL
48 hours after injection and 2.5 ng/mL at 6 months.6
Bowman and Pollack4 report values of 0.4–0.8 ng/mL at
88 to 98 days after a 300 μg dose.Thus,a 300-μg dose (in
the United States) would be undetectable at 6 months
(<1 ng/mL). It is much more likely that anti-D detected
at 6 months postinjection is the result of active, rather
than passive, immunization.
Early studies by Pollack et al.7 demonstrated that pri-
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